Today, once again, Novogen announced that it has filed a couple of patents. Not received a notice of allowance or won an opposition or anything of commercial significance, but you know, just paperwork. Well done to Andrew Heaton and the team for getting some cunning new technology put down on the page – and especially a new acronym! How exciting… “VAL-ID”, I like it! Hopefully this incredibly sexy new acronym will get lots of airplay in company investor presentations going forward. Hopefully you’ve also started the process of trademarking “VAL-ID” so that we can expect to see another awesome press release in the very near future.
Gosh, though … pretty relieved you exercised some restraint and didn’t call it “Ingenious Novogen’s Versatile Approach to Library-based Iterative Design”. That would have been AWKWARD !
I’d also just like to express my deepest thank you to Iain Ross. I was worried that when a industry veteran, a “heavy hitter” got at the helm of Novogen, that we’d stop seeing this kind of ASX disclosure from the company (classified as “price sensitive”, no less!). I was so afraid that following Graham’s departure to go and do proper early stage drug development somewhere else, we wouldn’t get any more news flow about filed patents, or pre-clinical animal studies. You know, all the lightweight ASX chatter that makes Novogen, well, so “novo”. I always suspected you guys were best buddies and it just really makes me happy to see you keep the flame alive, a sort of homage to Graham’s wholesome style of company engagement with its shareholders.
Obviously, given that you’ve got headhunters out there looking for a new CEO (globally), it’s a great time to truly showcase the company’s culture at its finest. You know, really propagate that image of international-standard quality, maturity and credibility.